Unknown PHASE3 INTERVENTIONAL 2-arm NCT01619462

Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children (PCV1103)

A Study of Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines to Inform Policy Regarding Pneumococcal Vaccination of Papua New Guinean Children

Sponsor: Papua New Guinea Institute of Medical Research

Conditions Bacteraemia Meningitis Otitis Media Pneumonia Sepsis

Interventions Prevenar 13 and Synflorix

Updated 6 times since 2017 Last updated: Mar 20, 2014 Started: Nov 30, 2011 Primary completion: Apr 30, 2014 Completion: Nov 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01619462, this PHASE3 trial focuses on Bacteraemia and Meningitis and remains ongoing. Sponsored by Papua New Guinea Institute of Medical Research, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE3

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Papua New Guinea Institute of Medical Research
The University of Western Australia

Data source: Papua New Guinea Institute of Medical Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Goroka, Papua New Guinea